We conducted a cohort study involving 670 RA patients, stratified into four groups according to anti-Ro52 and anti-Ro60 antibody status: Ro52+/Ro60+, Ro52+/Ro60−, Ro52−/Ro60+, and Ro52−/Ro60−. Here, TRIM21 is linked to rheumatoid arthritis.